AGC株式会社
AGCグループはグローバルにバイオ医薬品原薬の受託開発・製造事業を展開しています。豊富な実績と高度な技術に基づき、バイオ医薬品原薬の開発段階から商用段階までをサポートしています。
会社カテゴリー：原薬・添加剤・中間体、製造受託機関(CMO)、医薬品製造、再生医療関連
主サービス提供地域：日本、アメリカ合衆国、ヨーロッパ(イギリス以外)、イギリス、アジア
製品・サービス詳細
Mammalian, Bacteria, and Yeast-based Success
At AGC Biologics we have developed over 200 mammalian, bacteria and yeast-based processes, giving us the insight necessary to identify and optimize process parameters that are critical for achieving a high-quality, cost-effective manufacturing process.
Developing an efficient, scalable, validated and cost-effective manufacturing process is essential for success in today’s competitive biologics markets. Whether you need assistance developing a de novo process, improving existing processes, or preparing to manufacture your product, you will benefit from our expertise.
Cell Therapy and Viral Vectors for Gene Therapy
Our cell therapy process development capabilities include a proprietary production platform for T-cells and HSCs transduction, process characterization studies, cell biology analytical testing and development, and more.
AGC Biologics cellular biology laboratories have the ability to support important processes like CD34+ and T-cells transduction, as well as T-cell immunomagnetic selection, culturing, and transduction by viral vector.
Our viral vector process development capabilities also utilize proprietary platforms (adhesion and suspension) for adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RV). The AGC Biologics viral vector process development services include process characterization studies, verification batches, and cell banking.
For both cell therapy and viral vectors, we offer pilot batches and full-scale batches for new clients prior to transfer in GMP.
Process Development Expertise from Pilot through Commercial Scale
Our scientists apply decades of expertise to ensure the most effective processes for manufacturing your product at a pilot, clinical and commercial scale. Our broad knowledge of cGMP manufacturing enables us to successfully transfer existing processes into our facility or develop a new, innovative process when needed to meet your program objectives. We have amassed the skills and resources to develop late-stage processes that utilize innovative production techniques, resulting in maximum scalability and efficient process transferability.
This expertise, combined with single-use and high throughput technologies, allows for rapid development and streamlined transfer, helping to accelerate your product development and commercialization timelines.